POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

FEATURES


Viewpoints

New ASCO/CCO Prostate Cancer Guidelines Emphasize Quality of Life

New ASCO/CCO Prostate Cancer Guidelines Emphasize Quality of Life

The right time for American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) on metastatic castration-resistant prostate cancer.

Certain Kind of Baldness at Age 45 Linked to Increased Risk of Prostate Cancer

Certain Kind of Baldness at Age 45 Linked to Increased Risk of Prostate Cancer

A recent study published in the Journal of Clinical Oncology links male pattern baldness with elevated risk of aggressive prostate cancer.

Feature Articles

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer

Human epidermal growth factor receptor-2 is overexpressed in up to 30% of breast cancers; indicative of poor prognosis.

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success.

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.

Slideshows

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).

Table of Contents

Slide 3: Indication, Dosage, ...

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

From the Advisory Board

The Resurgence of Interest in Immune Therapy for Metastatic Renal Carcinoma

The Resurgence of Interest in Immune Therapy for Metastatic Renal Carcinoma

Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.

CME

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs